Medication Prescribing Patterns at a Youth Mental Health Service: A Single Center Retrospective Cross-sectional Study

被引:0
作者
Dinh, Angela [1 ]
El-Den, Sarira [1 ]
Collins, Jack C. [1 ]
Hamilton, Blake [2 ,3 ]
Janiszewski, Connie M. S. [2 ,3 ]
Fowler, Donna [2 ,3 ]
O'Reilly, Claire L. [1 ]
机构
[1] Univ Sydney, Sch Pharm, Fac Med & Hlth, Camperdown, NSW, Australia
[2] Univ Sydney, Brain & Mind Ctr, Camperdown, NSW, Australia
[3] Univ Sydney, Brain & Mind Ctr, Headspace Camperdown, Camperdown, NSW, Australia
关键词
mental illness; psychotropic medication; young people; youth mental health service; CLINICAL-PRACTICE GUIDELINES; NEW-ZEALAND COLLEGE; PSYCHOTROPIC MEDICATIONS; YOUNG-PEOPLE; QUETIAPINE; AUSTRALIA; HEADSPACE; ADOLESCENTS; CHILDREN; INSOMNIA;
D O I
10.1089/cap.2024.0140
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective: Rates of mental illness among young people remain elevated, and the utilization of youth mental health services is expected to increase. Yet, there is limited knowledge on real-world medication usage and prescribing at these services. Hence, the aim of this study was to explore the medication prescribing patterns at a headspace center, an Australian youth mental health service.Methods: A retrospective cross-sectional study of medical records was conducted. Demographic data, clinical information, prescribed medications, and reasons for use of young people who attended an intake assessment at headspace Camperdown over a 13-month period, February 2021-February 2022, were analyzed. Data collection focused on medication molecule, strength, dose, prescriber designation, and indication. Data were analyzed descriptively.Results: Records for 608 participants were included. The median age at intake was 19.9 years old (interquartile range: 16.1-22.4), and most participants identified as female (n = 372, 61.2%). Anxiety (n = 246, 40.5%) and low mood (n = 95, 15.6%) were the most common presenting concerns. Almost half of participants (n = 291, 47.9%) reported using medication/s at intake, and almost one in five participants (n = 119, 19.6%) were prescribed a medication at the service. The most prescribed medications at headspace were melatonin (24.0%) and quetiapine (12.3%), as well as the antidepressants escitalopram (15.1%), sertraline (11.2%), and fluoxetine (7.3%).Conclusions: This study provides insights into the prescribing practices at a single headspace center. Further investigations are needed to explore the impacts of off-label prescribing for young people, particularly in relation to melatonin and quetiapine, where safety and efficacy in young people have not been well established.
引用
收藏
页数:9
相关论文
共 65 条
  • [1] American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, (2013)
  • [2] Anderson SL, Vande Griend JP, Quetiapine for insomnia: A review of the literature, Am J Health Syst Pharm, 71, 5, pp. 394-402, (2014)
  • [3] Andrews G, Bell C, Boyce P, Et al., Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder, Aust N Z J Psychiatry, 52, 12, pp. 1109-1172, (2018)
  • [4] National Study of Mental Health and Wellbeing. 2020-22
  • [5] Australian Medicines Handbook 2023, (2023)
  • [6] Barczyk ZA, Rucklidge JJ, Eggleston M, Et al., Psychotropic medication prescription rates and trends for New Zealand children and adolescents 2008-2016, J Child Adolesc Psychopharmacol, 30, 2, pp. 87-96, (2020)
  • [7] Boafo A, Greenham S, Sullivan M, Et al., Medications for sleep disturbance in children and adolescents with depression: A survey of Canadian child and adolescent psychiatrists, Child Adolesc Psychiatry Ment Health, 14, 1, (2020)
  • [8] Brett J, Karanges EA, Daniels B, Et al., Psychotropic medication use in Australia, 2007 to 2015: Changes in annual incidence, prevalence and treatment exposure, Aust N Z J Psychiatry, 51, 10, pp. 990-999, (2017)
  • [9] Brimblecombe N, Knapp M, Murguia S, Et al., The role of youth mental health services in the treatment of young people with serious mental illness: 2-year outcomes and economic implications, Early Interv Psychiatry, 11, 5, pp. 393-400, (2017)
  • [10] Cleare A, Pariante CM, Young AH, Et al., Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines, J Psychopharmacol, 29, 5, pp. 459-525, (2015)